$LGND News
Last published 1w ago
- 1w agoLGNDLigand Third Quarter 2026 Earnings Call - LIGAND PHARMACEUTICALS INCEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to the Ligand Third Quarter Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please pre
- 1w agoLGNDLIGAND PHARMACEUTICALS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoLGNDLigand Reports Third Quarter 2026 Financial ResultsGlobeNewswireThird-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.501; Reaffirms Revenue Guidance Conference call begins at
- 2w agoLGNDLigand to Participate in November Investor ConferencesGlobeNewswireJUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: UBS
- 2w agoLGNDLigand to Host Investor Day on December 8, 2026GlobeNewswireJUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00
- 3w agoLGNDLigand to Report Third Quarter 2026 Financial Results on October 29, 2026GlobeNewswireJUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026. The company
- 1mo agoLGNDSydnexis Announces Royalty Agreement with Ligand for Ryjunea®Business Wire$23 million upfront payment immediately monetizes future royalties associated with Ryjunea in Europe, the Middle East, and Africa Capital further strengthens Sydnexis’ balance sheet as Company continues to advance
- 2mo agoLGNDLigand to Participate in September Investor ConferencesGlobeNewswireJUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells
- 3mo agoOBIOMDTLGNDOrchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business UpdatesGlobeNewswireThe BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary data
- 3mo agoLGNDLigand Reports Second Quarter 2026 Financial ResultsGlobeNewswireSecond quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Conference call begins at 8:30 a.m. Eastern Time today
- 3mo agoLGNDLigand to Report Second Quarter 2026 Financial Results on August 6, 2026GlobeNewswireJUPITER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026. The company
- 4mo agoXOMAXOMAOXOMAPLGNDXOMA Royalty Announces Closing of Its Acquisition by LigandGlobeNewswireEMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has completed its previously announced acquisition of XOMA Royalty.
- 4mo agoLGNDLigand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty AssetsGlobeNewswireAcquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term
- 4mo agoLGNDLigand Announces Pricing of Upsized $625 Million Convertible Senior Notes OfferingGlobeNewswireOpportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution
- 4mo agoLGNDLigand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031GlobeNewswireOpportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution
- 5mo agoLGNDLigand Announces 2026 Investor Day in New York CityGlobeNewswireJUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 10:30 a.m. Eastern
- 5mo agoLGNDLigand to Participate in June Investor ConferencesGlobeNewswireJUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Stifel
- 6mo agoLGNDMDTOBIOOrchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesGlobeNewswireOrchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE:MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial
- 6mo agoLGNDLigand First Quarter 2026 Earnings CallLIGAND PHARMACEUTICALS INCEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to Ligand First Quarter 2026 Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please pr
- 6mo agoLGNDLigand Reports First Quarter 2026 Financial ResultsGlobeNewswireFirst quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA
- 6mo agoLGNDMDTOBIOOrchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing AgreementGlobeNewswire$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra
- 6mo agoLGNDLigand to Participate in May Investor ConferencesGlobeNewswireJUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C.
- 6mo agoLGNDLigand To Acquire Xoma RoyaltyLIGAND PHARMACEUTICALS INCEarnings Call Transcriptsladies and gentlemen thank you for standing by my name is krista and i will be your conference operator today at this time i would like to welcome everyone to ligand pharmaceuticals to acquire zoma royalty all lines have
- 6mo agoLGNDXOMALigand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty AggregatorGlobeNewswireTransaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across
- 6mo agoLGNDLigand to Report First Quarter 2026 Financial Results on May 7, 2026GlobeNewswireJUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will
- 7mo agoLGNDTVTXLigand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGSGlobeNewswireFILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026
- 7mo agoLGNDLigand Advances Strategic Growth with Expanded and Strengthened Business Development TeamGlobeNewswireJUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents
- 8mo agoLGNDLigand to Participate in March Investor ConferencesGlobeNewswireJUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences:
- 8mo agoLGNDLigand Fourth Quarter 2025 EarningsLIGAND PHARMACEUTICALS INCEarnings Call TranscriptsThank you for standing by, and welcome to Ligand's 4th Quarter 2025 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer sess
- 8mo agoLGNDLigand Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireRobust financial performance driven by full year 2025 royalty revenue growth of 48% Reiterating 2026 financial guidance of $245-$285 million in revenues and adjusted earnings per diluted share1 of $8.00-$9.00
- 9mo agoLGNDLigand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026GlobeNewswireJUPITER, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.
- 9mo agoLGNDLigand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireJUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a
- 11mo agoLGNDLigand Hosts 2025 Investor Day and Introduces 2026 GuidanceGlobeNewswireIntroduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core
- 1y agoLGNDMDTOBIOOrchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business UpdatesGlobeNewswireSecured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and
- 1y agoLGNDPTHSPelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes FinancingGlobeNewswireAcquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in
- 1y agoLGNDLigand Reports Third Quarter 2025 Financial Results and Raises GuidanceGlobeNewswireThird quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and adjusted earnings
- 1y agoLGNDLigand to Participate in November Investor ConferencesGlobeNewswireJUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in
- 1y agoLGNDLigand to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewswireJUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company
- 1y agoLGNDLigand to Host Investor Day on December 9, 2025GlobeNewswireJUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:30
- 1y agoLGNDLigand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure PatientsGlobeNewswireSecond-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled™ approved product JUPITER, Fla., Oct. 09,
- 1y agoLGNDArecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292GlobeNewswireThis announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR"). Arecor Therapeutics plc("Arecor" or the "Company")
- 1y agoLGNDLigand to Participate in September Investor ConferencesGlobeNewswireJUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in
- 1y agoLGNDLigand Announces Closing of Convertible Senior Notes OfferingGlobeNewswireJUPITER, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today that it completed its previously announced offering (the "offering") of 0.75% convertible
- 1y agoLGNDMDTOBIOOrchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business UpdatesGlobeNewswireSecured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed capital from Medtronic
- 1y agoLGNDLigand Announces Pricing of $400 Million Convertible Senior Notes OfferingGlobeNewswireJUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today the pricing of $400.0 million aggregate principal amount of 0.75% convertible senior notes
- 1y agoLGNDLigand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030GlobeNewswireJUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today its intention to offer $400.0 million aggregate principal amount of convertible senior notes
- 1y agoLGNDLigand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoLGNDLigand Reports Second Quarter 2025 Financial Results and Raises GuidanceGlobeNewswireSecond quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings
- 1y agoLGNDMDTOBIOOrchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity OfferingsGlobeNewswire$56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand$55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from
- 1y agoLGNDMDTOBIOLigand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMedGlobeNewswire• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to invest $10 million in